Literature DB >> 21427442

Survey of aspirin use in Sturge-Weber syndrome.

Mihee J Bay1, Eric H Kossoff, Christoph U Lehmann, T Andrew Zabel, Anne M Comi.   

Abstract

Sturge-Weber syndrome is a rare congenital disorder. Seizures, stroke-like episodes, glaucoma, headache, and developmental delay are frequently associated features. An Internet-based questionnaire was designed to assess the frequency of use, effectiveness, and safety of aspirin treatment in Sturge-Weber syndrome. Thirty-four of 98 subjects who completed the survey reported having used aspirin. The mean number of reported stroke-like episodes was reduced from 1.1 to 0.3 per month in the year after starting aspirin (n = 26, p = .014). The median number of seizures was significantly reduced from 3 to 1 episodes per month (n = 21, p = .002). Thirty-nine percent of subjects reported a history of complications (predominantly increased bruising or gum/nose bleeding) while on aspirin; however, none reported discontinuing aspirin because of side effects. Our study showed a significant relative reduction in both self-reported seizure frequency and stroke-like episodes after starting aspirin. It also suggests that low-dose aspirin can be safely used in these patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21427442     DOI: 10.1177/0883073810388646

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  14 in total

Review 1.  Current Therapeutic Options in Sturge-Weber Syndrome.

Authors:  Anne Comi
Journal:  Semin Pediatr Neurol       Date:  2015-11-11       Impact factor: 1.636

2.  Sturge-Weber Syndrome.

Authors:  Bharath A Chhabria; Prasanth Bala Subramanium; Ram Nampoothiri; Ashish Bhalla; Subhash Varma
Journal:  J Clin Diagn Res       Date:  2017-02-01

3.  Toward a better understanding of stroke-like episodes in Sturge-Weber syndrome.

Authors:  Csaba Juhász
Journal:  Eur J Paediatr Neurol       Date:  2020-02-14       Impact factor: 3.140

4.  Focal venous hypertension as a pathophysiologic mechanism for tissue hypertrophy, port-wine stains, the Sturge-Weber syndrome, and related disorders: proof of concept with novel hypothesis for underlying etiological cause (an American Ophthalmological Society thesis).

Authors:  Cameron F Parsa
Journal:  Trans Am Ophthalmol Soc       Date:  2013-09

Review 5.  A Multidisciplinary Consensus for Clinical Care and Research Needs for Sturge-Weber Syndrome.

Authors:  Alejandro J De la Torre; Aimee F Luat; Csaba Juhász; Mai Lan Ho; Davis P Argersinger; Kara M Cavuoto; Mabel Enriquez-Algeciras; Stephanie Tikkanen; Paula North; Craig N Burkhart; Harry T Chugani; Karen L Ball; Anna Lecticia Pinto; Jeffrey A Loeb
Journal:  Pediatr Neurol       Date:  2018-04-18       Impact factor: 3.372

6.  Stimulant use in patients with sturge-weber syndrome: safety and efficacy.

Authors:  Eboni I Lance; Kira E Lanier; T Andrew Zabel; Anne M Comi
Journal:  Pediatr Neurol       Date:  2013-11-21       Impact factor: 3.372

Review 7.  Anesthetic management of pediatric patients with Sturge-Weber syndrome: our experience and a review of the literature.

Authors:  Puneet Khanna; Bikash Ranjan Ray; Srinivas Rhagvan Govindrajan; Renu Sinha; Praveen Talawar
Journal:  J Anesth       Date:  2015-07-21       Impact factor: 2.078

Review 8.  Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.

Authors:  Victoria C Ziesenitz; Tatjana Welzel; Madelé van Dyk; Patrick Saur; Matthias Gorenflo; Johannes N van den Anker
Journal:  Paediatr Drugs       Date:  2022-09-02       Impact factor: 3.930

9.  Aspirin use in Sturge-Weber syndrome: side effects and clinical outcomes.

Authors:  Eboni I Lance; Aditya K Sreenivasan; T Andrew Zabel; Eric H Kossoff; Anne M Comi
Journal:  J Child Neurol       Date:  2012-10-30       Impact factor: 1.987

10.  Hypoxic-ischemic injury causes functional and structural neurovascular degeneration in the juvenile mouse retina.

Authors:  Ismail S Zaitoun; Pawan K Shahi; Andrew Suscha; Kore Chan; Gillian J McLellan; Bikash R Pattnaik; Christine M Sorenson; Nader Sheibani
Journal:  Sci Rep       Date:  2021-06-16       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.